(-0.08%) 5 464.96 points
(-0.33%) 38 981 points
(0.29%) 17 769 points
(0.46%) $81.20
(-3.48%) $2.66
(-0.88%) $2 310.40
(-0.17%) $28.82
(1.56%) $1 001.80
(0.27%) $0.936
(0.70%) $10.68
(0.38%) $0.791
(-0.18%) $87.33
Live Chart Being Loaded With Signals
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases...
Stats | |
---|---|
本日の出来高 | 9 308 |
平均出来高 | 98 925 |
時価総額 | 407.41M |
EPS | $-10.50 ( Q1 | 2024-03-31 ) |
次の収益日 | ( $-0.810 ) 2024-08-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.167 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | English Emily | Sell | 0 | Common Stock |
2024-04-09 | English Emily | Sell | 14 254 | Stock Option (Right to Buy) |
2024-04-09 | English Emily | Sell | 23 433 | Stock Option (Right to Buy) |
2024-04-08 | Singer Michael | Buy | 377 208 | Common Stock |
2024-04-08 | Singer Michael | Buy | 110 151 | Common Stock |
INSIDER POWER |
---|
75.69 |
Last 44 transactions |
Buy: 16 103 370 | Sell: 2 254 554 |
ボリューム 相関
Cartesian Therapeutics, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cartesian Therapeutics, 相関 - 通貨/商品
Cartesian Therapeutics, 財務諸表
Annual | 2023 |
収益: | $26.00M |
総利益: | $24.45M (94.03 %) |
EPS: | $-42.58 |
FY | 2023 |
収益: | $26.00M |
総利益: | $24.45M (94.03 %) |
EPS: | $-42.58 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cartesian Therapeutics,
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company\'s lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。